SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories’ arm launches authorized generic of Evoxac in US

09 Oct 2012 Evaluate

Ranbaxy Laboratories’ (RLL) wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc (RPI) has launched the authorized generic cevimeline hydrochloride 30 mg capsules in the US market, under an agreement with Daiichi Sankyo, Inc.

Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo, Inc. under the brand name Evoxac. Evoxac generated total annualized sales of $62.4 million in the US (IMS - MAT June 2012).

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. The company is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×